BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 36256645)

  • 1. Analytical and clinical validation of a custom 15-gene next-generation sequencing panel for the evaluation of circulating tumor DNA mutations in patients with advanced non-small-cell lung cancer.
    Chow YP; Zainul Abidin N; Kow KS; Tho LM; Wong CL
    PLoS One; 2022; 17(10):e0276161. PubMed ID: 36256645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction of a reference material panel for detecting
    Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J
    J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.
    Roosan MR; Mambetsariev I; Pharaon R; Fricke J; Husain H; Reckamp KL; Koczywas M; Massarelli E; Bild AH; Salgia R
    Chest; 2021 Sep; 160(3):1095-1107. PubMed ID: 33878340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective.
    Aggarwal A; Sharma S; Brar Z; Kumar V; Kumar A; Katara R; Mohanty SK
    Pathol Res Pract; 2024 Jan; 253():155013. PubMed ID: 38096714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
    Liu J; Liu Y
    Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic profiling of NGS-based ctDNA from Chinese non-small cell lung cancer patients.
    Xi Y; Bai Z; Gao S; Guo J; Zhang Z; Zhang H; Qu L; Xu B; Wang W; Shan G; Cui W; Bai W; Ji X
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):8573-8580. PubMed ID: 37186065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next‑generation sequencing‑based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her‑2 and TP53 mutations in patients with non‑small cell lung cancer.
    Jing C; Mao X; Wang Z; Sun K; Ma R; Wu J; Cao H
    Mol Med Rep; 2018 Aug; 18(2):2191-2197. PubMed ID: 29956783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients.
    Wang B; Wu S; Huang F; Shen M; Jiang H; Yu Y; Yu Q; Yang Y; Zhao Y; Zhou Y; Pan B; Liu T; Guo W
    Clin Chem Lab Med; 2019 Sep; 57(10):1501-1510. PubMed ID: 31339850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Revolutionizing Non-Small Cell Lung Cancer Diagnosis: Ultra-High-Sensitive ctDNA Analysis for Detecting Hotspot Mutations with Long-term Stored Plasma.
    Lee JY; Jeon S; Jun HR; Sung CO; Jang SJ; Choi CM; Chun SM
    Cancer Res Treat; 2024 Apr; 56(2):484-501. PubMed ID: 37871897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Next-Generation Sequencing, Quantitative PCR, and Sanger Sequencing for Mutation Profiling of EGFR, KRAS, PIK3CA and BRAF in Clinical Lung Tumors.
    Gao J; Wu H; Shi X; Huo Z; Zhang J; Liang Z
    Clin Lab; 2016; 62(4):689-96. PubMed ID: 27215089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the clinical application of detecting EGFR, KRAS, PIK3CA and BRAF mutations in patients with non-small cell lung cancer using next-generation sequencing.
    Xu X; Yang Y; Li H; Chen Z; Jiang G; Fei K
    Scand J Clin Lab Invest; 2016 Sep; 76(5):386-92. PubMed ID: 27215271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
    Li Y; Zhang FS; Guo L; Ying JM
    Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
    [No Abstract]   [Full Text] [Related]  

  • 13. Exhaled Breath Condensate (EBC) analysis of circulating tumour DNA (ctDNA) using a lung cancer specific UltraSEEK oncogene panel.
    Ryan DJ; Toomey S; Smyth R; Madden SF; Workman J; Cummins R; Sheehan K; Fay J; Naidoo J; Breathnach OS; Morris PG; Grogan L; O'Brien ME; Sulaiman I; Hennessy BT; Morgan RK
    Lung Cancer; 2022 Jun; 168():67-73. PubMed ID: 35526313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing.
    Chen KZ; Lou F; Yang F; Zhang JB; Ye H; Chen W; Guan T; Zhao MY; Su XX; Shi R; Jones L; Huang XF; Chen SY; Wang J
    Sci Rep; 2016 Aug; 6():31985. PubMed ID: 27555497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-platform comparison of next-generation sequencing and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for detecting KRAS/NRAS/BRAF/PIK3CA mutations in cfDNA from metastatic colorectal cancer patients.
    Xu X; Huang F; Cao M; Chen X; Wang H; Jiang H; Yu Y; Shen M; Yang Y; Wang B; Liu T; Guo W
    J Clin Lab Anal; 2021 Sep; 35(9):e23818. PubMed ID: 34403504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002.
    Couraud S; Vaca-Paniagua F; Villar S; Oliver J; Schuster T; Blanché H; Girard N; Trédaniel J; Guilleminault L; Gervais R; Prim N; Vincent M; Margery J; Larivé S; Foucher P; Duvert B; Vallee M; Le Calvez-Kelm F; McKay J; Missy P; Morin F; Zalcman G; Olivier M; Souquet PJ;
    Clin Cancer Res; 2014 Sep; 20(17):4613-24. PubMed ID: 25013125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive Genomic Analysis of Patients With Non-Small-Cell Lung Cancer Using Blood-Based Circulating Tumor DNA Assay: Findings From the BFAST Database of a Single Center in Taiwan.
    Wang HY; Ho CC; Lin YT; Liao WY; Chen CY; Shih JY; Yu CJ
    JCO Precis Oncol; 2024 Jan; 8():e2300314. PubMed ID: 38190582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next generation MUT-MAP, a high-sensitivity high-throughput microfluidics chip-based mutation analysis panel.
    Schleifman EB; Tam R; Patel R; Tsan A; Sumiyoshi T; Fu L; Desai R; Schoenbrunner N; Myers TW; Bauer K; Smith E; Raja R
    PLoS One; 2014; 9(3):e90761. PubMed ID: 24658394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients.
    Martín Martorell P; Huerta M; Compañ Quilis A; Abellán R; Seda E; Blesa S; Chaves FJ; Dualde Beltrán D; Roselló Keränen S; Franco J; Insa A
    Clin Lung Cancer; 2017 Nov; 18(6):e395-e402. PubMed ID: 28550959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non-Small Cell Lung Cancer (LC-SCRUM-Liquid).
    Sugimoto A; Matsumoto S; Udagawa H; Itotani R; Usui Y; Umemura S; Nishino K; Nakachi I; Kuyama S; Daga H; Hara S; Miyamoto S; Kato T; Sakakibara-Konishi J; Tabata E; Nakagawa T; Kawaguchi T; Sakai T; Shibata Y; Izumi H; Nosaki K; Zenke Y; Yoh K; Goto K
    Clin Cancer Res; 2023 Apr; 29(8):1506-1514. PubMed ID: 36201167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.